Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series

J Eur Acad Dermatol Venereol. 2024 Feb 29. doi: 10.1111/jdv.19929. Online ahead of print.
No abstract available

Publication types

  • Letter